Yin-Lei Han, Huan-Huan Yin, Chen Li, Jiangyue Du, Yi He, Yi-Xin Guan
{"title":"Discovery of New Pentapeptide Inhibitors Against Amyloid-β Aggregation Using Word2Vec and Molecular Simulation.","authors":"Yin-Lei Han, Huan-Huan Yin, Chen Li, Jiangyue Du, Yi He, Yi-Xin Guan","doi":"10.1021/acschemneuro.4c00661","DOIUrl":null,"url":null,"abstract":"<p><p>Alzheimer's disease (AD) is characterized by the aggregation of amyloid-β (Aβ) peptides into toxic oligomers and fibrils. The efficacy of existing peptide inhibitors based on the central hydrophobic core (CHC) sequence of Aβ42 remains limited due to self-aggregation or poor inhibition. This study aimed to identify novel pentapeptide inhibitors with high similarity and low binding energy to the CHC region LVFFA using a new computational screening workflow based on Word2Vec and molecular simulation. The antimicrobial peptides and human brain protein sequences were used for training the Word2Vec model. After tuning the parameters of the Word2Vec model, 1017 pentapeptides with high similarity to LVFFA were identified. Molecular docking was employed to estimate the affinity of the pentapeptides for the target of Aβ14-42 pentamer, and 103 peptides with favorable docking scores were obtained. Finally, five pentapeptides with a low binding energy and high binding stability via molecular dynamics simulation were experimentally validated using thioflavin T assays. Surprisingly, one pentapeptide, i.e., PALIR, exhibited significant inhibition surpassing the positive control LPFFN. This study demonstrates an effective combinatorial strategy to discover new peptide inhibitors. With PALIR representing a promising lead candidate, further optimization of PALIR could aid in the development of improved therapies to prevent amyloid toxicity in AD.</p>","PeriodicalId":13,"journal":{"name":"ACS Chemical Neuroscience","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Chemical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acschemneuro.4c00661","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Alzheimer's disease (AD) is characterized by the aggregation of amyloid-β (Aβ) peptides into toxic oligomers and fibrils. The efficacy of existing peptide inhibitors based on the central hydrophobic core (CHC) sequence of Aβ42 remains limited due to self-aggregation or poor inhibition. This study aimed to identify novel pentapeptide inhibitors with high similarity and low binding energy to the CHC region LVFFA using a new computational screening workflow based on Word2Vec and molecular simulation. The antimicrobial peptides and human brain protein sequences were used for training the Word2Vec model. After tuning the parameters of the Word2Vec model, 1017 pentapeptides with high similarity to LVFFA were identified. Molecular docking was employed to estimate the affinity of the pentapeptides for the target of Aβ14-42 pentamer, and 103 peptides with favorable docking scores were obtained. Finally, five pentapeptides with a low binding energy and high binding stability via molecular dynamics simulation were experimentally validated using thioflavin T assays. Surprisingly, one pentapeptide, i.e., PALIR, exhibited significant inhibition surpassing the positive control LPFFN. This study demonstrates an effective combinatorial strategy to discover new peptide inhibitors. With PALIR representing a promising lead candidate, further optimization of PALIR could aid in the development of improved therapies to prevent amyloid toxicity in AD.
期刊介绍:
ACS Chemical Neuroscience publishes high-quality research articles and reviews that showcase chemical, quantitative biological, biophysical and bioengineering approaches to the understanding of the nervous system and to the development of new treatments for neurological disorders. Research in the journal focuses on aspects of chemical neurobiology and bio-neurochemistry such as the following:
Neurotransmitters and receptors
Neuropharmaceuticals and therapeutics
Neural development—Plasticity, and degeneration
Chemical, physical, and computational methods in neuroscience
Neuronal diseases—basis, detection, and treatment
Mechanism of aging, learning, memory and behavior
Pain and sensory processing
Neurotoxins
Neuroscience-inspired bioengineering
Development of methods in chemical neurobiology
Neuroimaging agents and technologies
Animal models for central nervous system diseases
Behavioral research